itae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices.
Company profile
Ticker
NVTA
Exchange
Website
CEO
Sean Emerson George
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Locus Development Inc
SEC CIK
Corporate docs
Subsidiaries
ArcherDX, LLC • ArcherDX Clinical Services, Inc. • Ciitizen, LLC • Genelex India Private Limited • Genetic Solutions LLC • Genosity, LLC • Good Start Genetics, Inc. • Invitae Australia PTY LTD • Invitae Canada Inc. • Invitae Israel Inc Ltd. ...
NVTA stock data
Analyst ratings and price targets
Latest filings (excl ownership)
S-3
Shelf registration
17 Mar 23
8-K
Regulation FD Disclosure
14 Mar 23
8-K
Entry into a Material Definitive Agreement
8 Mar 23
8-K
Entry into a Material Definitive Agreement
1 Mar 23
POS AM
Prospectus update (post-effective amendment)
1 Mar 23
POS AM
Prospectus update (post-effective amendment)
28 Feb 23
S-8
Registration of securities for employees
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Invitae Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Company Updates
28 Feb 23
POSASR
Automatic shelf registration (post-effective amendment)
28 Feb 23
Transcripts
NVTA
Earnings call transcript
2022 Q4
28 Feb 23
NVTA
Earnings call transcript
2022 Q3
8 Nov 22
NVTA
Earnings call transcript
2022 Q2
10 Aug 22
NVTA
Earnings call transcript
2022 Q1
4 May 22
NVTA
Earnings call transcript
2021 Q4
25 Feb 22
NVTA
Earnings call transcript
2021 Q3
9 Nov 21
NVTA
Earnings call transcript
2021 Q2
4 Aug 21
NVTA
Earnings call transcript
2021 Q1
5 May 21
NVTA
Earnings call transcript
2020 Q4
18 Feb 21
NVTA
Earnings call transcript
2020 Q3
6 Nov 20
Latest ownership filings
4
Thomas Brida
15 Mar 23
4
Robert L Nussbaum
15 Mar 23
4
Yafei Wen
15 Mar 23
4
Kenneth D. Knight
15 Mar 23
SC 13G/A
Casdin Capital, LLC
14 Feb 23
SC 13G/A
ARK Investment Management LLC
10 Feb 23
SC 13G/A
Nikko Asset Management Americas, Inc.
10 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G/A
Sumitomo Mitsui Trust Holdings, Inc.
3 Feb 23
4
William H Osborne
30 Jan 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 267.52 mm | 267.52 mm | 267.52 mm | 267.52 mm | 267.52 mm | 267.52 mm |
| Cash burn (monthly) | (no burn) | 55.50 mm | 35.06 mm | 262.60 mm | 27.34 mm | 41.08 mm |
| Cash used (since last report) | n/a | 148.40 mm | 93.74 mm | 702.16 mm | 73.11 mm | 109.84 mm |
| Cash remaining | n/a | 119.12 mm | 173.78 mm | -434.64 mm | 194.41 mm | 157.68 mm |
| Runway (months of cash) | n/a | 2.1 | 5.0 | -1.7 | 7.1 | 3.8 |
Institutional ownership, Q4 2022
73.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 274 |
| Opened positions | 40 |
| Closed positions | 46 |
| Increased positions | 84 |
| Reduced positions | 87 |
| 13F shares | Current |
|---|---|
| Total value | 333.77 bn |
| Total shares | 181.35 mm |
| Total puts | 1.08 mm |
| Total calls | 1.77 mm |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| ARK Investment Management | 27.07 mm | $50.36 bn |
| Vanguard | 22.59 mm | $42.01 bn |
| BLK Blackrock | 21.77 mm | $40.49 bn |
| CMTDF Sumitomo Mitsui Trust | 17.26 mm | $32.10 bn |
| Nikko Asset Management Americas | 17.26 mm | $32.10 bn |
| Casdin Capital | 9.04 mm | $16.81 bn |
| Baker Bros. Advisors | 8.40 mm | $15.63 bn |
| STT State Street | 7.34 mm | $13.65 bn |
| Geode Capital Management | 4.27 mm | $7.97 bn |
| Rock Springs Capital Management | 3.10 mm | $5.76 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 13 Mar 23 | Yafei Wen | Common Stock | Sell | Dispose S | No | No | 1.41 | 2,625 | 3.70 k | 443,749 |
| 13 Mar 23 | Kenneth D. Knight | Common Stock | Sell | Dispose S | No | No | 1.41 | 1,853 | 2.61 k | 517,042 |
| 13 Mar 23 | Nussbaum Robert L | Common Stock | Sell | Dispose S | No | No | 1.41 | 2,625 | 3.70 k | 447,907 |
| 13 Mar 23 | Brida Thomas | Common Stock | Sell | Dispose S | No | No | 1.41 | 2,625 | 3.70 k | 437,642 |
Press releases
Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology
16 Mar 23
Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing
15 Mar 23
Invitae's PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage
6 Mar 23
Invitae to Present at the TD Cowen 43rd Annual Health Care Conference
1 Mar 23
Invitae Announces Convertible Notes and Share Exchange and New Convertible Notes Issuance
28 Feb 23